Genprex (GNPX) Stock Analysis

What Genprex does

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

Key metrics

ETFs linked to GNPX

Broad-market and Healthcare sector ETFs an investor holding Genprex is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GNPX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Genprex?

Genprex trades under the ticker GNPX on NASDAQ.

Which exchange is GNPX listed on?

GNPX is listed on NASDAQ.

What sector does Genprex operate in?

Genprex is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze GNPX in a portfolio?

PortView shows GNPX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.